Alamandine
Alamandine 性质
| 密度 | 1.42±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.28±0.20(Predicted) |
| 颜色 | 白色至米白色 |
Alamandine 用途与合成方法
Alamandine is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine. Alamandine is also an endogenous peptide identified in human blood.
Alamandine elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling.
Alamandine decreases secretion, expression, and blood levels of leptin. Alamandine induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes.
Alamandine (0.15 μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide.
| Animal Model: | Male spontaneously hypertensive rats (SHRs, 50-week-old) |
| Dosage: | 0.15 μL/h (~50 μg/kg/day) |
| Administration: | Administered by mini-osmotic pumps; for 6 weeks |
| Result: | Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function. |
Alamandine 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-P3108 | 1 mg | 1727 | ||
| 2024-04-30 | HY-P3108 | Alamandine | 1176306-10-7 | 5mg | 3800 |
